We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q3?
Read MoreHide Full Article
Biogen Inc. (BIIB - Free Report) , a well-known name in the multiple sclerosis (MS) market, will be reporting third-quarter 2016 earnings on Oct 26, before market open.Last quarter, the company delivered a positive earnings surprise of 11.09%.
Biogen’s performance has been pretty impressive, with consistent positive surprises. The average earnings beat over the last four quarters is 11.39%.
Let’s see how things are shaping up for this announcement.
Factors to Consider
Since the emergence of the first progressive multifocal leukoencephalopathy (PML)-related death in a patient on oral MS drug, Tecfidera, investor focus has been on its performance.
Biogen is working on growing Tecfidera sales. Tecfidera demand is expected to remain relatively stable in the U.S. in the quarter. Outside the U.S., Tecfidera’s performance in Germany will remain in focus.
While Tysabri should remain on a stable trajectory, the number of patients using Avonex and Plegridy combined will continue to decline as patients move toward oral treatments.
Zinbryta is expected to contribute modestly to revenues in the U.S. and EU. Zinbryta was launched in collaboration with AbbVie Inc. (ABBV - Free Report) in August.
Meanwhile, Biogen intends to spin off its hemophilia business in early 2017. The new company will be named Bioverativ and will focus on the discovery, research, development and commercialization of treatments for hemophilia and other blood disorders.
Head count reduction and restructuring initiatives announced last year are expected to benefit operating expenses by about $250 million this year.
Focus on Call: Investor focus on the third-quarter call will remain on Tecfidera’s scrip trends, news regarding additional PML cases, pipeline progress and acquisition plans.
Earnings Whispers
Our proven model does not conclusively show that Lilly is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: The Earnings ESP is -1.41% as the Most Accurate estimate stands at $4.90 while the Zacks Consensus Estimate is pegged higher at $4.97.
Zacks Rank: Lilly’s Zacks Rank #3 increases the predictive power of ESP. However, we need to have a positive ESP to be confident about an earnings beat.
We caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Some stocks in the large-cap healthcare sector that have both a positive Earnings ESP and a favorable Zacks Rank are:
Novartis AG (NVS - Free Report) with an Earnings ESP of +0.84% and a Zacks Rank #3. The company is scheduled to release results on Oct 25.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q3?
Biogen Inc. (BIIB - Free Report) , a well-known name in the multiple sclerosis (MS) market, will be reporting third-quarter 2016 earnings on Oct 26, before market open.Last quarter, the company delivered a positive earnings surprise of 11.09%.
Biogen’s performance has been pretty impressive, with consistent positive surprises. The average earnings beat over the last four quarters is 11.39%.
BIOGEN INC Price and EPS Surprise
BIOGEN INC Price and EPS Surprise | BIOGEN INC Quote
Let’s see how things are shaping up for this announcement.
Factors to Consider
Since the emergence of the first progressive multifocal leukoencephalopathy (PML)-related death in a patient on oral MS drug, Tecfidera, investor focus has been on its performance.
Biogen is working on growing Tecfidera sales. Tecfidera demand is expected to remain relatively stable in the U.S. in the quarter. Outside the U.S., Tecfidera’s performance in Germany will remain in focus.
While Tysabri should remain on a stable trajectory, the number of patients using Avonex and Plegridy combined will continue to decline as patients move toward oral treatments.
Zinbryta is expected to contribute modestly to revenues in the U.S. and EU. Zinbryta was launched in collaboration with AbbVie Inc. (ABBV - Free Report) in August.
Meanwhile, Biogen intends to spin off its hemophilia business in early 2017. The new company will be named Bioverativ and will focus on the discovery, research, development and commercialization of treatments for hemophilia and other blood disorders.
Head count reduction and restructuring initiatives announced last year are expected to benefit operating expenses by about $250 million this year.
Focus on Call: Investor focus on the third-quarter call will remain on Tecfidera’s scrip trends, news regarding additional PML cases, pipeline progress and acquisition plans.
Earnings Whispers
Our proven model does not conclusively show that Lilly is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: The Earnings ESP is -1.41% as the Most Accurate estimate stands at $4.90 while the Zacks Consensus Estimate is pegged higher at $4.97.
Zacks Rank: Lilly’s Zacks Rank #3 increases the predictive power of ESP. However, we need to have a positive ESP to be confident about an earnings beat.
We caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Some stocks in the large-cap healthcare sector that have both a positive Earnings ESP and a favorable Zacks Rank are:
Amgen Inc. (AMGN - Free Report) , which is slated to report results on Oct 27. The company has an Earnings ESP of +1.79% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Novartis AG (NVS - Free Report) with an Earnings ESP of +0.84% and a Zacks Rank #3. The company is scheduled to release results on Oct 25.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>